Recent advances and challenges of repurposing nanoparticle-based drug delivery systems to enhance cancer immunotherapy

Lim, Seungho; Park, Jooho; Shim, Man Kyu; Um, Wooram; Yoon, Hong Yeol; Ryu, Ju Hee; Lim, Dong-Kwon; Kim, Kwangmeyung

doi:10.7150/thno.38425

Nanotheranostics 2025; 9(1): 38-51. Full text PDF

Nanotheranostics 2025; 9(1): 31-37. Full text PDF

Nanotheranostics

International Journal of Biological Sciences

International Journal of Medical Sciences

Journal of Cancer

open access Global reach, higher impact

Full Text | PDF

Theranostics 2019; 9(25):7906-7923. doi:10.7150/thno.38425 This issue Cite

Review

Recent advances and challenges of repurposing nanoparticle-based drug delivery systems to enhance cancer immunotherapy

Seungho Lim^1*, Jooho Park^1*, Man Kyu Shim¹, Wooram Um¹, Hong Yeol Yoon¹, Ju Hee Ryu¹, Dong-Kwon Lim², Kwangmeyung Kim^1,2✉

1. Center for Theragnosis, Biomedical Research Institute, Korea Institute of Science and Technology (KIST), 5, Hwarangno 14-gil, Seongbuk-gu, Seoul, 02792, Republic of Korea
2. KU-KIST Graduate School of Converging Science and Technology, Korea University, 145, Anam-ro, Seongbuk-gu, Seoul, 02841, Republic of Korea.
^*These authors contributed equally to this work

Citation:

Lim S, Park J, Shim MK, Um W, Yoon HY, Ryu JH, Lim DK, Kim K. Recent advances and challenges of repurposing nanoparticle-based drug delivery systems to enhance cancer immunotherapy. Theranostics 2019; 9(25):7906-7923. doi:10.7150/thno.38425. https://www.thno.org/v09p7906.htm

Other styles

Abstract

Cancer immunotherapy is an attractive treatment option under clinical settings. However, the major challenges of immunotherapy include limited patient response, limited tumor specificity, immune-related adverse events, and immunosuppressive tumor microenvironment. Therefore, nanoparticle (NP)-based drug delivery has been used to not only increase the efficacy of immunotherapeutic agents, but it also significantly reduces the toxicity. In particular, NP-based drug delivery systems alter the pharmacokinetic (PK) profile of encapsulated or conjugated immunotherapeutic agents to targeted cancer cells or immune cells and facilitate the delivery of multiple therapeutic combinations to targeted cells using single NPs. Recently, advanced NP-based drug delivery systems were effectively utilized in cancer immunotherapy to reduce the toxic side effects and immune-related adverse events. Repurposing these NPs as delivery systems of immunotherapeutic agents may overcome the limitations of current cancer immunotherapy. In this review, we focus on recent advances in NP-based immunotherapeutic delivery systems, such as immunogenic cell death (ICD)-inducing drugs, cytokines and adjuvants for promising cancer immunotherapy. Finally, we discuss the challenges facing current NP-based drug delivery systems that need to be addressed for successful clinical application.

Keywords: Nanoparticles, drug delivery system, immunogenic cell death, adjuvants, cytokines, and cancer immunotherapy

Citation styles

APA

Lim, S., Park, J., Shim, M.K., Um, W., Yoon, H.Y., Ryu, J.H., Lim, D.K., Kim, K. (2019). Recent advances and challenges of repurposing nanoparticle-based drug delivery systems to enhance cancer immunotherapy. Theranostics, 9(25), 7906-7923. https://doi.org/10.7150/thno.38425.

ACS

Lim, S.; Park, J.; Shim, M.K.; Um, W.; Yoon, H.Y.; Ryu, J.H.; Lim, D.K.; Kim, K. Recent advances and challenges of repurposing nanoparticle-based drug delivery systems to enhance cancer immunotherapy. Theranostics 2019, 9 (25), 7906-7923. DOI: 10.7150/thno.38425.

NLM

CSE

Lim S, Park J, Shim MK, Um W, Yoon HY, Ryu JH, Lim DK, Kim K. 2019. Recent advances and challenges of repurposing nanoparticle-based drug delivery systems to enhance cancer immunotherapy. Theranostics. 9(25):7906-7923.

This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/). See http://ivyspring.com/terms for full terms and conditions.